Collapse navigation.
To deliver better everyday health with humanity
Our Win as One strategy is how we will realise our ambitions
Markets we operate in
Global categories
Consumers reached
Revenue FY2025
| Six market categories | Oral Health | Vitamins, Minerals & Supplements (VMS) | Pain Relief | Respiratory Health | Digestive Health | Therapeutic Skin Health & Other |
|---|---|---|---|---|---|---|
| Key superior brands |  |
 |
 |
 |
 |
 |
| Category size/ Haleon position¹ | £30bn/#12 | £66bn/#1 | £20bn/#1 | £32bn/#2 | £20bn/#1 | £34bn/#33 |
| Combined category growth at 3–4%4 | ||||||
1. Global Data £MSP 2024 (‘Oralcare’, mapping to Oral Health). Nicholas Hall £MSP 2024 (VMS; ‘Analgesics’ mapping to Pain Relief; ‘Cough Cold & Allergy’ plus ‘Smoking Control’ mapping to Respiratory Health; ‘Gastrointestinals’ mapping to Digestive Health; and ‘Dermatologicals’ plus ‘Lifestyle CHC’ (excluding ‘Smoking Control’) mapping to Therapeutic Skin Health & Other). 2024 is the latest date to which data is available for the consumer healthcare market as a whole, beyond our individual categories.
2. Relates to Therapeutic Oral Health only, from: Haleon’s analysis of third-party data including IQVIA, Circana, Nielsen et al (2024). Data set based on Haleon global category standards. Haleon is #3 across the entire Oral Health category.
3. Relates to Therapeutic Skin Health only, mapped to the Nicholas Hall ‘Dermatologicals’ category alone. Haleon is #5 across the entire Therapeutic Skin Health & Other category.
4. Haleon’s analysis of third-party market data including IQVIA, Circana, NIQ et al (2024). Data set based on Haleon global category standards.
| Adjusted results2 | Reported results | ||||
|---|---|---|---|---|---|
Twelve months ended 31 December |
2025 |
vs 2024 |
2025 |
vs 2024 |
|
Organic revenue growth |
3.0%2 |
Revenue |
£11,030m |
(1.8)% |
|
North America |
(0.4)%3 |
||||
EMEA and LatAm |
4.7%3 |
||||
APAC |
5.2%3 |
||||
Adjusted gross profit |
£7,193m |
4.4%4 |
Gross profit |
£7,080m |
3.8% |
Adjusted gross margin |
65.2% |
220 bps4 |
Gross margin |
64.2% |
350bps |
Adjusted operating profit |
£2,526m |
10.5%3 |
Operating profit |
£2,412m |
9.3% |
Adjusted operating profit margin |
22.9% |
160 bps3 |
Operating profit margin |
21.9% |
230bps |
Adjusted diluted earnings per share |
18.8p |
5.0% |
Diluted earnings per share |
18.5p |
17.8% |
Free cash flow |
£1,913m |
£(31)m |
Net cash flow from operating activities |
£2,634m |
£333m |
Net debt/Adjusted EBITDA |
2.6x |
(0.2)x |
|||
1. The commentary in this announcement contains forward-looking statements and should be read in conjunction with the cautionary note on page 21
2. Organic revenue growth, organic operating profit growth, adjusted operating profit, adjusted operating profit margin, adjusted gross profit, adjusted gross profit margin, adjusted diluted earnings per share, free cash flow, adjusted profit attributable to shareholders, net debt and adjusted EBITDA are non-IFRS measures; definitions and calculations of non-IFRS measures can be found on pages 21 to 29
3. On an organic basis, at constant currency and excludes the impact of divestments, acquisitions, manufacture and supply agreements (MSAs) relating to divestments and closure of production sites
4. At constant currency
5. Includes net proceeds from divestments in 2024 including £325m in gross proceeds with £(100)m in associated tax payments, primarily related to ChapStick
6. Refers to Consumer Health market. Market share statements throughout this announcement are estimates based on the Group’s analysis of third party market data of revenue for FY 2025 including IQVIA, IRI and Nielsen data. Represents % of brand-market combinations gaining or maintaining share (this analysis covers c.90% of Haleon’s total revenue).
7. As of 5 February 2026
Haleon is pronounced "Hay-Lee-On". The name is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength’.
We operate in 170 markets.
We have 6 global product categories. They are:
Haleon owns Sensodyne, Polident, parodontax, Aquafresh, Centrum, Emergen-C, Caltrate, Panadol, Advil, Otrivine, Theraflu, Flonase, Robitussin Tums, ENO, Benefiber, Fenistil and Zovirax.
Our brands combine scientific rigour with a deep understanding of how people manage their health each day. Because we focus solely on everyday health, every product we make is shaped by specialist expertise, consumer insight and a commitment to improving people’s wellbeing with humanity.
Our products are available through pharmacies, supermarkets, online retailers and other trusted outlets worldwide. Availability varies by market, but we strive to ensure our brands are accessible wherever people shop for their everyday health needs.
We are proud of the impact we have on people around the world. In 2025, Haleon helped 1.4 billion consumers look after their everyday health, out of a global population of 8 billion. We aim to serve a billion more by 2030.
Each brand is designed to help people take control of a specific aspect of their health — from sensitive teeth to joint pain, immunity, congestion, digestion and more. By providing effective, high-quality products, we help people feel better today while supporting their long-term wellbeing.
Sustainability is built into how we develop and deliver our products. This includes reducing packaging waste, improving recyclability, sourcing responsibly and lowering our environmental impact. We continually invest in innovations that help our brands support both better everyday health and a healthier planet.
Our purpose is to deliver better everyday health with humanity. Haleon operates in an attractive and highly relevant global consumer health sector worth around £200bn today. We are well positioned to benefit from favourable long-term macro trends including the global focus on health and wellness, ageing populations, and a growing middle class, particularly in emerging markets.
Haleon, as a leading consumer company today, started from a single apothecary shop in London, opened in 1715 by Silvanus Bevan. Haleon listed as an independent company on the London and New York stock exchanges in July 2022.
Haleon is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers, throughout all stages of their lives.
Haleon operates in over 170 markets, with offices, research centres and manufacturing sites around the world. Our global headquarters is in London, United Kingdom, supported by major hubs across Europe, the Americas and Asia–Pacific.
This global presence helps us understand diverse consumer needs and make everyday health accessible everywhere.
Haleon is well positioned in the Consumer Health sector, an attractive, evolving sector supported by long-term trends. As socioeconomic and geopolitical dynamics shift, we see growing opportunities to drive reach and optimise our supply chain. We have strong positions in attractive categories, which help us address evolving consumer needs and regulatory trends. We are investing in digital and technology, and have competitive strengths in pharmacies and with experts, to help us adapt to the evolving channel landscape.
We have two clear ambitions:
We will achieve this by putting everyday health in more hands, strengthening our portfolio of superior brands, improving efficiency across our business and unlocking the full potential of our people.
Underpinned by our purpose – to deliver better everyday health with humanity – we are driving an agile and performance-focused culture, empowering our people to innovate, collaborate and reach their full potential so we can meet the evolving needs of our consumers across the world.
Related
